Cargando…
Screen for MicroRNA and Drug Interactions in Breast Cancer Cell Lines Points to miR-126 as a Modulator of CDK4/6 and PIK3CA Inhibitors
Background: Breast cancer (BC) represents the most common cancer in women worldwide. Due to its heterogeneous nature, breast cancer management might benefit from differential treatments toward personalized medicine. Additionally, drug resistance is a common phenomenon. We systematically investigated...
Autores principales: | Baldassari, Federica, Zerbinati, Carlotta, Galasso, Marco, Corrà, Fabio, Minotti, Linda, Agnoletto, Chiara, Previati, Maurizio, Croce, Carlo M., Volinia, Stefano |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5968201/ https://www.ncbi.nlm.nih.gov/pubmed/29868122 http://dx.doi.org/10.3389/fgene.2018.00174 |
Ejemplares similares
-
Loss of miR-204 expression is a key event in melanoma
por: Galasso, Marco, et al.
Publicado: (2018) -
The Network of Non-coding RNAs in Cancer Drug Resistance
por: Corrà, Fabio, et al.
Publicado: (2018) -
SNPs and Somatic Mutation on Long Non-Coding RNA: New Frontier in the Cancer Studies?
por: Minotti, Linda, et al.
Publicado: (2018) -
Profiling of the Predicted Circular RNAs in Ductal In Situ and Invasive Breast Cancer: A Pilot Study
por: Galasso, Marco, et al.
Publicado: (2016) -
Heterogeneous expression of EPCAM in human circulating tumour cells from patient-derived xenografts
por: Agnoletto, Chiara, et al.
Publicado: (2018)